2023
Survival analysis of patients treated at oncology practices with more aggressive end-of-life practice patterns.
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Survival analysis of patients treated at oncology practices with more aggressive end-of-life practice patterns. Journal Of Clinical Oncology 2023, 41: 6562-6562. DOI: 10.1200/jco.2023.41.16_suppl.6562.Peer-Reviewed Original ResearchReal-world overall survivalSystemic anticancer therapySurvival analysisNon-small cell lungCox proportional hazards modelPractice-level factorsRenal cell carcinomaProportional hazards modelCommon cancer typesDe-identified databaseElectronic health recordsAdvanced diseaseAdult patientsHazard ratioMetastatic diseaseMost patientsOverall survivalSurvival benefitSystemic treatmentAggressive endPrimary outcomeCell carcinomaCell lungPrimary exposureCancer patientsCurrent use of the National Surgical Quality Improvement Program surgical risk calculator in academic surgery: a mixed-methods study
Miller S, Azar S, Farrelly J, Salzman G, Broderick M, Sanders K, Anto V, Patel N, Cordova A, Schuster K, Jones T, Kodadek L, Gross C, Morton J, Rosenthal R, Becher R. Current use of the National Surgical Quality Improvement Program surgical risk calculator in academic surgery: a mixed-methods study. Surgery In Practice And Science 2023, 13: 100173. PMID: 37502700, PMCID: PMC10373440, DOI: 10.1016/j.sipas.2023.100173.Peer-Reviewed Original ResearchNSQIP Surgical Risk CalculatorSurgical Risk CalculatorNonelective casesRisk calculatorNational Surgical Quality Improvement Program Surgical Risk CalculatorHigh-risk patientsGeneral clinical practiceSpecific clinical scenariosCross-sectional studyElectronic health recordsFrail patientsPrimary outcomeHalf of respondentsPreoperative assessmentContemporary surgical practiceClinical practiceClinical scenariosSurgical practicePast monthPatientsSurgeonsTraining statusSurrogate consentPotential interventionsHealth records
2022
Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial
Sedrak M, Sun C, Ji J, Cohen H, Gross C, Tew W, Klepin H, Wildes T, Dotan E, Freedman R, O'Connor T, Chow S, Fenton M, Moy B, Chapman A, Dale W, Katheria V, Kuderer N, Lyman G, Magnuson A, Muss H. Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial. Journal Of Clinical Oncology 2022, 41: 316-326. PMID: 36455189, PMCID: PMC9839299, DOI: 10.1200/jco.22.01440.Peer-Reviewed Original ResearchConceptsLow relative dose intensityRelative dose intensityAdjuvant chemotherapyHOPE trialDose intensityOlder patientsOlder womenBreast cancer benefitPrespecified secondary analysisCurative-intent treatmentInferior survival outcomesChemotherapy dose intensityKaplan-Meier methodLow performance statusMultivariable logistic regressionLog-rank testOverall survival probabilityToxic side effectsCancer benefitOverall survivalPerformance statusStandard chemotherapySupportive carePrimary outcomeSurvival outcomes
2019
Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents.
Giri S, Huntington S, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A, Neparidze N. Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents. Journal Of Clinical Oncology 2019, 37: 8044-8044. DOI: 10.1200/jco.2019.37.15_suppl.8044.Peer-Reviewed Original ResearchOverall survivalMultiple myelomaPerformance statusMultivariable Cox survival analysisMedian overall survivalPoor performance statusLines of therapyKaplan-Meier methodCox regression analysisDays of diagnosisWorse overall survivalCox survival analysisLog-rank testReal-world treatmentCommon genetic mutationsHigh-risk mutationsSitu hybridization testingElectronic health recordsISS stageReal-world practiceMedian ageMeier methodOS independentPrimary outcomeSpecific regimens
2017
Physician volume and discontinuation of rituximab during lymphoma treatment.
Huntington S, Long J, Hoag J, Wang R, Zeidan A, Giri S, Gore S, Ma X, Gross C, Davidoff A. Physician volume and discontinuation of rituximab during lymphoma treatment. Journal Of Clinical Oncology 2017, 35: 6593-6593. DOI: 10.1200/jco.2017.35.15_suppl.6593.Peer-Reviewed Original ResearchNon-Hodgkin lymphomaEarly discontinuationRituximab discontinuationPhysician volumeProvider volumeEnd Results-Medicare dataB-cell non-Hodgkin lymphomaCell non-Hodgkin lymphomaCox proportional hazards modelDiscontinuation of rituximabSevere infusion reactionsRetrospective cohort studyImpact of discontinuationDays of initiationProportional hazards modelDose-dependent mannerRituximab cyclesRituximab initiationInfusion reactionsOverall survivalCohort studyPrimary outcomeSystemic treatmentLymphoma treatmentRelative risk
2015
Association between provider-level factors and lymph node dissection outcomes during radical prostatectomy: A national cancer database analysis.
Kiechle J, Wang E, Yu J, Gross C, Abouassaly R, Cherullo E, Smaldone M, Shah N, Trinh Q, Sun M, Kim S. Association between provider-level factors and lymph node dissection outcomes during radical prostatectomy: A national cancer database analysis. Journal Of Clinical Oncology 2015, 33: 89-89. DOI: 10.1200/jco.2015.33.7_suppl.89.Peer-Reviewed Original ResearchPelvic lymph node dissectionHigh-risk prostate cancerLymph node countRobotic-assisted radical prostatectomyOpen radical prostatectomyRadical prostatectomyProstate cancerLymph nodesSurgical approachHospital characteristicsCommunity hospitalNode countNational Cancer Database AnalysisTime of RPUnderwent radical prostatectomyLymph node dissectionNational Cancer DatabaseLow-volume hospitalsProvider-level factorsPopulation-based cohortAggressive prostate cancerNode dissectionVolume hospitalsPrimary outcomeMultivariable analysis
2014
PS1-44: Time to Surgery for Melanoma
Lott J, Soulos P, Aminawung J, Gross C. PS1-44: Time to Surgery for Melanoma. Clinical Medicine & Research 2014, 12: 78-78. PMCID: PMC4453318, DOI: 10.3121/cmr.2014.1250.ps1-44.Peer-Reviewed Original ResearchCases of melanomaDermatologic careRetrospective cohort studyPatient-level factorsElixhauser Comorbidity IndexICD-9 codesMultivariate logistic regressionSurgical procedure codesMelanoma-related deathHospital referral regionsMedicare administrative claimsClustering of casesPrior melanomaComorbidity indexCohort studySurgical resectionSurgical therapyPrimary outcomeSurgical delayIncident melanomaMedian timeRegional diseaseMedicare databaseCutaneous melanomaSkin biopsies
2012
Anemia and functional disability in older adults with cancer.
Owusu C, Tew W, Hardt M, Mohile S, Klepin H, Gross C, Gajra A, Lichtman S, Ramani R, Katheria V, Zavala L, Hurria A. Anemia and functional disability in older adults with cancer. Journal Of Clinical Oncology 2012, 30: 9109-9109. DOI: 10.1200/jco.2012.30.15_suppl.9109.Peer-Reviewed Original ResearchFunctional disabilityProspective studyOlder adultsMulti-center prospective studyUnintentional weight lossCorrection of anemiaRandomized-controlled trialPre-treatment variablesOlder ptsChemotherapy toxicityGeriatric assessmentPatient agePrimary outcomeMean HbFunctional statusInstrumental activitiesDaily livingAnemiaAdvanced stageMultivariate analysisAge 65Secondary analysisModifiable strategiesBivariate analysisLogistic regression